Cerebral venous sinus thrombosis associated with essential thrombocytosis in a pediatric patient

被引：6

作者：

Jensen, Ashley W.

Tefferi, Ayalew

Arndt, Carola A. S.

机构：

[1] Mayo Clin, Div Hematol & Oncol, Coll Med, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Radiat Oncol, Coll Med, Rochester, MN 55905 USA

[3] Mayo Clin, Div Pediat Hematol & Oncol, Coll Med, Rochester, MN 55905 USA

来源：

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2007年 / 29卷 / 03期

关键词：

essential thrombocytosis; hydroxyurea; venous sinus thrombosis;

D O I：

10.1097/MPH.0b013e3180377b9c

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Essential thrombocytosis (ET) is an uncommon pediatric hematologic disorder that can result in thrombotic complications, including cerebral venous sinus thrombosis (CVST). Although CVST associated with ET is exceedingly rare, it can be devastating to the patient. We here report a pediatric case of CVST associated with ET. The patient was treated with hydroxyurea and warfarin, which was later replaced by low-dose aspirin. Platelet counts were well controlled after 16 months of follow-up, and no further thrombotic events occurred. Mucositis was the main adverse effect of treatment.

引用

页码：156 / 159

页数：4

共 18 条

[1] Indications for lowering platelet numbers in essential thrombocythemia [J].

Barbui, T .

SEMINARS IN HEMATOLOGY, 2003, 40 (01) :22-25

[2] Hydroxyurea corrects the dysregulated L-selectin expression and increased H2O2 production of polymorphonuclear neutrophils from patients with sickle cell anemia [J].

Benkerrou, M ;

Delarche, C ;

Brahimi, L ;

Fay, M ;

Vilmer, E ;

Elion, J ;

Gougerot-Pocidalo, MA ;

Elbim, C .

BLOOD, 2002, 99 (07) :2297-2303

[3] HYDROXYUREA FOR PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND A HIGH-RISK OF THROMBOSIS [J].

CORTELAZZO, S ;

FINAZZI, G ;

RUGGERI, M ;

VESTRI, O ;

GALLI, M ;

RODEGHIERO, F ;

BARBUI, T .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) :1132-1136

[4] Essential thrombocythemia in children [J].

Dror, Y ;

Zipursky, A ;

Blanchette, VS .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1999, 21 (05) :356-363

[5]

Falanga A, 2000, BLOOD, V96, P4261

[6] Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis [J].

Finazzi, G ;

Ruggeri, M ;

Rodeghiero, F ;

Barbui, T .

BLOOD, 2003, 101 (09) :3749-3749

[7] Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia [J].

Harrison, CN ;

Campbell, PJ ;

Buck, G ;

Wheatley, K ;

East, CL ;

Bareford, D ;

Wilkins, BS ;

van der Walt, JD ;

Reilly, JT ;

Grigg, AP ;

Revell, P ;

Woodcock, BE ;

Green, AR ;

Pearson, TC ;

Conneally, E ;

Crawley, C ;

Cross, NCP ;

Hall, G ;

Hunt, B ;

Lucas, G ;

Ludlam, C ;

McMullin, MF ;

Oscier, D ;

Radia, D ;

Reilly, JT ;

Robinson, G ;

Culligan, DJ ;

Tighe, J ;

Watson, HG ;

Warren, AJ ;

Awaad, MO ;

Obeid, D ;

Cuthbert, RJG ;

Kyle, A ;

Chan-Lam, D ;

Paul, B ;

Cuthbert, RJG ;

McMullin, MF ;

Morris, TCM ;

Johnson, RJ ;

Fegan, C ;

Milligan, DW ;

Galloway, MJ ;

Williamson, PJ ;

Newton, LJ ;

Williams, AT ;

Abboudi, Z ;

Ryan, K ;

Lush, R ;

Blundell, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (01) :33-45

[8] Incidence of essential thrombocythaemia in children [J].

Hasle, H .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (03) :751-751

[9]

IOB I, 1979, SURG NEUROL, V11, P439

[10] Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature [J].

Liozon, E ;

Brigaudeau, C ;

Trimoreau, F ;

Desangles, F ;

Fermeaux, V ;

Praloran, V ;

Bordessoule, D .

HEMATOLOGY AND CELL THERAPY, 1997, 39 (01) :11-18

← 1 2 →